News & Events about Cognition Therapeutics Inc.
International Journal of Molecular Science Review Presents Mechanistic Rationale for Sigma-2 Receptor Modulation in Alzheimers Disease, Dementia with Lewy Bodies and Geographic AtrophyNEW YORK, April 12, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that a review ...
Globe Newswire
2 months ago
PURCHASE, N.Y., March 27, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc.(Nasdaq: CGTX) (the Company or Cognition) has released its fourth Conversations video podcast, a two-part conversation about dementia with Lewy bodies (DLB) focusing on the overlapping symptoms and pathology of DLB, ...
Globe Newswire
2 months ago
- CEO Participating on Panel Hosted by Alzheimers Drug Discovery Foundation -NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) will be presenting results of a proteomic biomarker meta-analysis of cerebrospinal fluid, or CSF, samples from the initial cohort of ...
Globe Newswire
2 months ago
Conference Call and Live Audio Webcast Scheduled for Thursday, March 23, 2023, 8:00 a.m. ETPURCHASE, N.Y., March 16, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating ...
Globe Newswire
2 months ago
Conference Call and Live Audio Webcast Scheduled for Wednesday, March 23, 2023, 8:00 a.m. ETPURCHASE, N.Y., March 16, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating ...